Semaglutide Dosing Guide: Personalized Dosage & Clinical Factors

Last reviewed: May 17, 2026

Last updated: May 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide dosing for weight loss typically starts at 0.25 mg injected subcutaneously once weekly, with stepwise increases every 4 weeks until reaching a therapeutic maintenance dose of 1.7–2.4 mg weekly. Your exact dose depends on individual tolerability, clinical response, and provider guidance—not a predetermined fixed amount for everyone.

Understanding your semaglutide dose requires more than checking a prescription label. It involves recognizing how your metabolism, genetics, and medical history inform dosing decisions. PlexusDx supports this precision-wellness approach by combining clinical assessment with insights into your peptide pathway genetics, enabling more informed conversations with your healthcare provider about your personalized treatment plan.

Standard Semaglutide Dosing Protocol and Titration Schedule

The FDA-approved escalation protocol for semaglutide injections follows a four-week titration schedule. Week 1–4: 0.25 mg weekly. Week 5–8: 0.5 mg weekly. Week 9–12: 1.0 mg weekly. Week 13+: maintenance at 1.7 or 2.4 mg weekly. Gradual escalation reduces gastrointestinal side effects and allows your body to adapt.

Some patients reach therapeutic benefit at 1.0 or 1.7 mg and do not require the maximum 2.4 mg dose. Your provider may pause titration if weight loss plateaus or side effects emerge. Dose adjustments are individualized—there is no universal 'right' dose, only the dose that achieves your clinical goals with acceptable tolerability.

Key Clinical Factors That Influence Your Personalized Dose

Dosing decisions integrate several clinical dimensions: baseline body weight, presence of type 2 diabetes, kidney function, gastrointestinal tolerance, prior medication responses, and metabolic rate. Each factor influences whether a patient achieves weight loss success at 1.0 mg versus 2.4 mg, or whether slower titration reduces side effects while maintaining efficacy.

Clinical Factor	Impact on Dosing Decision
Body Weight & BMI	Patients with higher starting weight may require higher maintenance doses for optimal metabolic effect; lower BMI may achieve goals at lower doses.
GI Sensitivity History	Prior nausea or GI issues may necessitate slower titration, extended intervals between dose escalations, or a lower maintenance target.
Kidney Function (eGFR)	Mild-to-moderate renal impairment does not require dose adjustment; severe renal disease warrants provider consultation before initiation.
Baseline Metabolic Rate	Faster metabolism or history of weight loss resistance may influence whether 1.7 mg or 2.4 mg is targeted as maintenance dose.
Concurrent Medications	Certain medications affecting appetite or GI motility may interact; provider should review full medication list before dose escalation decisions.

Recognizing Therapeutic Response and When Dose Adjustments Occur

Therapeutic response typically emerges within 4–8 weeks at each dose level, with measurable weight loss often visible after 8–12 weeks of treatment. Your provider monitors not just weight reduction but also appetite suppression, blood sugar control, and side effect burden. If weight loss stalls despite adequate dosing, your provider may extend time at current dose or evaluate whether escalation is appropriate.

Dose reductions or holding periods may occur if patients experience intolerable nausea, vomiting, severe constipation, or signs of pancreatitis. This is not treatment failure—it reflects the provider's commitment to balancing efficacy with quality of life. Some patients achieve durable weight loss at doses lower than the FDA-recommended maximum and maintain that dose long-term.

Safety, Provider Oversight, and Who Should Use Semaglutide

Semaglutide is indicated for adults with a BMI ≥30 kg/m² or BMI ≥27 kg/m² with weight-related comorbidities (hypertension, type 2 diabetes, heart disease). Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or severe allergic reactions to semaglutide. Pregnancy is a contraindication; women of childbearing age should use contraception during treatment and for at least 2 months after discontinuation.

Qualified healthcare providers—physicians, nurse practitioners, or physician assistants with prescribing authority—should oversee dosing, titration, and monitoring. Your provider will assess kidney function, perform baseline cardiovascular screening if appropriate, and monitor for pancreatitis symptoms, gallbladder complications, or changes in vision. Do not self-escalate doses; all adjustments require provider approval and clinical reassessment.

Genetic and Biomarker Context for Personalized Dosing Conversations

Emerging research suggests that genetic variants in the GLP-1 receptor gene and related metabolic pathways may influence individual dose response and side effect tolerance. While genetic testing does not predict your exact semaglutide dose, understanding your genetic predispositions in peptide pathways can provide context for why your optimal dose may differ from a peer's dose.

Biomarkers such as fasting glucose, insulin resistance (HOMA-IR), inflammatory markers, and baseline weight loss history can inform more targeted dosing strategies. Some patients with high insulin resistance may achieve better metabolic control at slightly higher doses, while others with metabolic efficiency may respond well to lower doses. These conversations are most productive when guided by both clinical assessment and relevant genetic or biomarker insights.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context for how your genetic predispositions in GLP-1 receptor and metabolic pathways relate to dosing decisions. The test evaluates variants such as GLP1R rs6923761, GIPR rs1800437, MC4R rs17782313, and FTO rs9939609—markers that influence appetite regulation and metabolic response. This information should be interpreted with a qualified healthcare provider as part of a comprehensive dosing strategy, not as a predictor of your exact semaglutide dose.

Genetic predispositions identified in your Precision Peptide test may reveal whether your genetic profile aligns with sensitivity to GLP-1 therapies or suggests a lower inflammatory burden, which can support a more informed conversation with your provider about whether to target 1.0 mg, 1.7 mg, or 2.4 mg as your maintenance dose. However, genetics do not guarantee a specific dose response—clinical response, tolerability, and provider judgment remain paramount.

When combined with biomarker assessments (glucose, insulin, lipid panel) and your clinical history, PlexusDx genetic insights can support a more personalized conversation with your healthcare provider about dosing strategy, anticipated timeline to therapeutic response, and which dose escalation schedule may be most appropriate for your unique metabolic and genetic profile.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.